title: BPL plasma products: new source, enhanced products.
abstract: Bio Products Laboratory (BPL), the main fractionator of plasma-derived medicines, are undergoing a change from UK plasma to plasma from the USA. BPL aim to maintain continuity of supply and a seamless changeover, despite meticulous cleaning of its production plant and months of auditing by both the organization and regulatory authorities.
authors.affiliation: Regional Immunology Department, Birmingham Heartlands Hospital.
authors.forename: D S
authors.initials: DS
authors.lastname: Kumararatne
mesh_terms: D001771:Blood Banks / Q000458:organization & administration* / Q000592:standards; D001782:Blood Donors; D007562:Creutzfeldt-Jakob Syndrome / Q000175:diagnosis / Q000517:prevention & control; D006801:Humans; D018580:Mandatory Testing / Q000592:standards; D010949:Plasma; D013222:State Medicine; D006113:United Kingdom; D014481:United States